TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02643615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEP under TIVA
Description: Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
Study: NCT02322398

Intervention type: DRUG
Intervention: hMG
Description: 150-300 IU/d hMG
Study: NCT00533195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Methoxypsoralen
Description: 1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA1 phototherapy
Description: Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability.~No maintenance therapy except emollients.
Study: NCT00272467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: 1. Brand name: Mucosta® Tab.~2. Generic name: Rebamipide.~3. Chemical name:~   (±)-2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinon-4-yl\]propionic acid.~4. Formulation: Tablet (White, film-coated tablet).~5. Strength: One tablet contains rebamipide 100mg.~6. Storage condition: 15℃\~25℃.~7. Manufacturer: Korea Otsuka Pharmaceuticals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 1. Brand name: Losec® Cap.~2. Generic name: Omeprazole.~3. Chemical name:~5-melthoxy-2-{{{4-melthoxy-3.5-dlmethyl2-pyridinyl}methyl}sulp- hinyl}-1H-benzimidazole sodium. 4) Formulation: Capsule. 5) Strength: One capsule contains omeprazole 20mg. 6) Storage condition: 15℃\~25℃. 7) Manufacturer: AstraZenaca Korea.
Study: NCT02643615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEP under balanced anesth.
Description: Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
Study: NCT02860169

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Participants self-administered questionnaire and assessment
Description: Participants self-administered questionnaire and assessment includes Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participants self-administered questionnaire and assessment
Description: Participants self-administered questionnaire and assessment includes Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP.
Study: NCT02000050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: FOLFOX4

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomotherapy
Description: Tomotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME (Total Mesorectal Excision)
Description: TME (Total Mesorectal Excision)
Study: NCT03932032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment
Description: At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in social anxiety.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral Control Task
Description: At each of eight sessions, participants complete 160 computer administered trials wherein a pair of neutral stimuli is presented simultaneously and then followed immediately by a probe. NCT matches ABMT on duration, format, and number of trials, but does not engage attention to social threat and does not train attention.
Study: NCT02643615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
Study: NCT02643615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
Study: NCT01611116

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride solution 0.9%
Description: intravenous application added to standard chemotherapy on up to 8 predefined days during the course of study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: intravenous application added to standard chemotherapy on up to 16 predefined days during the course of study treatment
Study: NCT03735667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE Prime™ Transfemoral TAVR System XL
Description: ACURATE Prime™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
Study: NCT04526106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-4008
Description: RLY-4008 is an oral inhibitor of FGFR2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-4008
Description: RLY-4008 is an oral inhibitor of FGFR2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-4008
Description: RLY-4008 is an oral inhibitor of FGFR2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-4008
Description: RLY-4008 is an oral inhibitor of FGFR2
Study: NCT03435796

Intervention type: GENETIC
Group type: OTHER
Intervention: Gene-modified (GM) T cell therapy
Description: No investigational product will be administered
Study: NCT03789435

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire
Description: A questionnaire from which the session dedicated to the evaluation of the stump pain, the phantom limb and the sensation of the phantom limb has been extracted will be administered: this is the Prosthetic Evaluation Questionnaire (PEQ) validated in Italian by Ferrero et al. 2005.~In the questionnaire sent to patients will be asked also for anthropometric data (weight, height) in addition to the characteristics of the worn prosthesis and if they have followed a period of rehabilitation.The time of use of the prosthesis will be evaluated through the Houghton Scale of Prosthetic Use in People with Lower- Extremity Amputations (19)
Study: NCT04588064

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI PET/CT scan
Description: Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging within the specified time.
Study: NCT03073577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiaging Glycopeptide
Description: Antiaging Glycopeptide (PKX-001) will be supplemented to islet preservation medium during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays used in standard of care practice. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally by percutaneous transhepatic access.
Study: NCT04568603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: ISL 30 mg x 2 (60 mg total) capsules taken by mouth.
Study: NCT03731572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power Training
Description: Hip abductor-adductor resistance exercises at maximum execution speed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: Hip abductor-adductor resistance exercises at reduced execution speed
Study: NCT00713492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: human laboratory alcohol consumption.
Study: NCT04625686

Intervention type: BEHAVIORAL
Intervention: Mental Health Treatment
Description: Treatment of suicidal ideation

Intervention type: BEHAVIORAL
Intervention: Mental Health Treatment
Description: Treatment of suicidal ideation

Intervention type: BEHAVIORAL
Intervention: Mental Health Treatment
Description: Treatment of suicidal ideation
Study: NCT05598125

Intervention type: DEVICE
Intervention: electronic cigarette (e-cigarette)

Intervention type: DEVICE
Intervention: electronic cigarette (e-cigarette)

Intervention type: DEVICE
Intervention: conventional tobacco cigarette

Intervention type: DEVICE
Intervention: conventional tobacco cigarette
Study: NCT04086693

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV dressing
Description: Polyurethane and clear tape dressing used to secure peripheral IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard IV dressing plus a tissue adhesive peripheral IV securement device
Description: Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV
Study: NCT03713398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T4C-SMI
Description: T4C-SMI entails a 25-session, manualized intervention that is delivered in a closed-group format at least twice a week over a three-month period. The intervention curriculum includes three modules: nine sessions on social skills training, five sessions on cognitive restructuring activities, and ten sessions on problem-solving methods. Participants assigned to T4C-SMI receive this intervention in addition to any other prison mental health services that they are otherwise eligible to receive during their incarceration.
Study: NCT00837265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balugrastim
Description: Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.
Study: NCT03863587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLX12
Description: healthy volunters receive HLX12 (8mg/kg) once

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cyramza (Ramucirumab)
Description: healthy volunters receive Cyramza (Ramucirumab) 8mg/kg once
Study: NCT02307396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Study: NCT02841579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.
Study: NCT04406623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-172154
Description: The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Study: NCT02307396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Study: NCT02775500

Intervention type: DRUG
Intervention: apremilast
Description: Comparison of women exposed during pregnancy versus women who are not exposed to apremilast

Intervention type: DRUG
Intervention: apremilast
Description: Comparison of women exposed during pregnancy versus women who are not exposed to apremilast
Study: NCT00837265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balugrastim
Description: Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balugrastim
Description: Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.
Study: NCT02307396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perphenazine
Study: NCT00837265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balugrastim
Description: Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balugrastim
Description: Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Pegfilgrastim will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Pegfilgrastim will be administered per dose and schedule specified in the arm description.
Study: NCT04096170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV lidocaine
Description: Patients randomized to the IV lidocaine group will receive a 100 mg lidocaine bolus on induction then an infusion of 1.5 mg/kg/hr prior to incision. This infusion will continue throughout operation and into the PACU for 1 hour OR until the 2gm/250 mL D5W bag has been infused, whichever occurs first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: o Patients randomized to the placebo group will receive D5W solution (as this is the carrier for lidocaine) at the same volume and rate as the IV lidocaine.
Study: NCT01965613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Xilonix
Description: IV
Study: NCT04065841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor
Description: 100mcg+30mcg+10mcg capsules of tropifexor taken orally every day until the 140 mcg capsule of tropifexor taken orally every day is produced, then patients will switch to the single 140mcg capsule taken orally every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor
Description: 100mcg+30mcg+10mcg capsules of tropifexor taken orally every day until the 140 mcg capsule of tropifexor taken orally every day is produced, then patients will switch to the single 140mcg capsule taken orally every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licogliflozin
Description: 30mg tablet of licoglifozin taken orally every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licogliflozin
Description: 30mg tablet of licoglifozin taken orally every day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: licogliflozin placebo + tropifexor placebo
Study: NCT04039347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cyclosporine A 5 mg
Description: delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cyclosporine A 10 mg
Description: delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Study: NCT00837265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Regimen
Description: The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Regimen
Description: The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy Regimen
Description: The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Regimen
Description: The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Regimen
Description: The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
Study: NCT02533765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
Study: NCT04621175

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EAA+W & Carbohydrate
Description: Essential amino acid plus whey beverage with added carbohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EAA+W & Carbohydrate
Description: Essential amino acid plus whey beverage with added carbohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EAA+W & EAA
Description: Essential amino acid plus whey beverage with added essential amino acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EAA+W & EAA
Description: Essential amino acid plus whey beverage with added essential amino acid
Study: NCT04893733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B Complex
Description: Patients with established AKI will be randomized to received IV vitamin B complex each 1 hours for 5 consecutive days versus placebo.~Every patients will also received Institution standard of care for AKI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STOP AKI protocol
Description: STOP AKI protocols includes:~S: identify and treat sepsis. Standard measures should be followed to decrease the risk of infection. Close surveillance to identify early signs of infection with appropriate treatment T: avoid nephrotoxins. Avoidance of drugs harmful to the kidneys (e.g. NSAIDs, gentamicin) Care with intravenous iodinated contrast O: optimize blood pressure and optimize volume status. Avoid dehydration e.g. confused patient. Treat hypovolaemia promptly. Consider with-holding patient anti-hypertensives/diuretics until assessed after major surgery or if patient develops sepsis/hypovolemia P: Prevent harm. Identify the cause promptly and manage appropriately to prevent progression. Prevent complications by instituting prompt therapy. Identify drugs excreted through the kidneys and adjust drug doses promptly if AKI develops. Review fluid management plans to prevent inadequate or excessive intravenous fluid administration
Study: NCT00837265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Regimen
Description: The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy Regimen
Description: The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
Study: NCT04050436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cemiplimab
Description: Cemiplimab administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1
Description: RP1 administered intratumorally
Study: NCT05331053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Simvastation acts as a systemic LOX inhibitor.